A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.
Key Details
- 1The Path-IO model uses AI to analyze digital pathology slides from NSCLC patients.
- 2Tested on 797 patients (MD Anderson) and validated on 280 international patients (including Lung-MAP S1400I trial).
- 3The model stratified patients into high- and low-risk groups, doubling risk in the high-risk cohort.
- 4Path-IO outperformed PD-L1 biomarker: Path-IO C-indices up to 0.69 (OS) and 0.65 (PFS); PD-L1 indices as low as 0.50-0.58.
- 5Integrating radiomics and clinical data improved prediction performance further (C-index for OS to 0.75, PFS to 0.70).
- 6Study validated across real-world and phase III trial cohorts, though retrospective; prospective validation is the next step.
Why It Matters
This work demonstrates that advanced AI analysis of digital pathology can outperform traditional biomarkers in predicting immunotherapy outcomes. If validated further, such tools could help personalize treatment for cancer patients, offering a significant advance in precision oncology and imaging AI.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.